Blog / Archives
Bullish Action in Biotech Today
The melt-up resumes. Everyone talks about the really big correction but all we get is a measly 2-3% hit then onward and upward. Metals and materials were ~2% winners today and the NAZ was up 0.75%....
Rayno Snow Blog: LaNina Mid-Winter Drought
High and Dry in the West Why am I reporting on snow? There is none and little hope for the next seven days-maybe longer. If you like cool sunny dry weather come to SoCal.If you like snow go to NYC...
Amgen(AMGN) To Buy Biovex For Cancer Vaccine Technology
Biologics for Treatment of Cancer and Prevention of Infectious Disease Amgen(AMGN) and Biovex said today that both Boards approved the sale of privately held Biovex for $425M with milestone...
Life Science News Update:$700M in Fed Research Center at NIH; AD Diagnosis
Will the GOP cut the NIH budget? Turf battles at the Institutes to follow. Who knew there were only two breakthroughs in mental health drugs: Thorazine and Lithium? Federal Research Center Will Help...
Biotech Movers du jour: Clinical Data (CLDA) and Genoptix (GXDX)
Novartis (NVS) acquires Genoptix(GXDX $24.84) for $470M-Stock is up 25% The biotech diagnostics and tools sector was ignited today with acquisition of Genoptix, a provider of laboratory services for...
Venture Capital Recovers, Biotechnology Gets $3.7B in 2010
Venture Capitalists invested $21.8B in 2010 an increase of 19% over the prior year. Biotechnology was up 3% over the prior year to $3.7B with 460 deals. Software was the leader rising 20% to $4B....
Rayno Life Science Portfolio 2011:Time to Raise a Little Cash
Time for Caution-Raise Cash After the Big Q4 2010 Run Here are some guidelines for the Rayno Life Science Portfolio: Smaller cap high beta biopharma stocks are at risk. No new buys. Our mid-cap...
Biotech Stocks Sell-Off On Profit Taking: Traders Rule
Small to Mid Caps Off 3%+ Our Mid-Cap Index of biotech stocks was off 3% and more today. Among the big movers down on significant volume were: Alkermes (ALKS) down 4.19%, Arena (ARNA) down 4.25%,...
Reporting from the JPMorgan 29th Annual Healthcare Conference 2011
J.P.Morgan 29th Annual Healthcare Conference San Francisco, CA January 9-13 2011 Biotechnology: Bright Prospects For 2011 Rod Raynovich The J.P.Morgan Healthcare Conference was a hot ticket in a...
Rayno Life Science Portfolio Review:Celera(CRA),Qiagen(QGEN),and Gilead(GILD)
Review of the Laggards Celera (CRA $6.09) has been a laggard primarily because of disappointing results from the recent acquisition of Berkeley Heart Labs(BHL) which had reported sales $20M vs $24M...